Author:
Nie Lei,Lee Kyung Y.,Verdun Nicole,De Claro R. Angelo,Sridhara Rajeshwari
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference18 articles.
1. Nie L, Rubin E, Mehrotra N, Pinheiro J, Fernandes L, Roy A, et al. Rendering the 3 + 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy. Clin Cancer Res. 2016;22:2623–2629.
2. ASCO post report, FDA approves revised prescribing information for Ponatinib, authorizes resumption of drug sales and distribution. ASCO post, 2013. http://www.ascopost.com/ViewNews.aspx?nid=11871.
3. Cortes JE, Kim DW, Pinilla-IbarZ J, Le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of Ponatinib in Philadelphia chromosome-positive leukemias. N Eng J Med. 2013;369:1783–1796.
4. Cortes JE, Kantrrjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Eng J Med. 2012;367:2075–2088.
5. Buyes M. Randomized designs for early trials of new cancer treatments. Drug Inform J. 2000;34:387–396.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献